Earlier, Pfizer and Morphosys tied up in December 2003 to develop therapeutic antibodies.
Both the parties further extended their collaboration in 2006 under which Pfizer secured an option to begin several therapeutic antibody projects with MorphoSys.
MorphoSys chief scientific officer Marlies Sproll said they are delighted to add Pfizer to the list of partner companies running clinical trials with HuCAL-based antibodies.
"In total, seven different partners from the pharmaceutical and biotechnology industry are currently running clinical trials with our antibodies," Sproll said.